Scientific substantiation of the concept of pharmacoeconomic analysis of technologies for early diagnosis and pharmacotherapy of pulmonary arterial hypertension

Keywords: pulmonary arterial hypertension, diagnostic screening, pharmacoeconomic modelling, cost, profitability

Abstract

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure (hypertension) in the arteries of the lungs (pulmonary artery) for no apparent reason.

Because symptoms are nonspecific and physical signs may be subtle, the disease is often diagnosed at late stages. Over the past few decades, significant progress has been made in the field of pulmonary arterial hypertension. Technological progress allows to diagnose the disease in the early stages, as well as to better assess the severity of the disease.

Today, screening studies are becoming increasingly important to establish a clinical diagnosis and minimize lost opportunities without timely diagnosis, especially in patients with idiopathic PAH.

Therefore, the issue of early diagnosis of patients with suspected PAH and confirmation of the diagnosis is a very important and urgent issue today.

The objective of the paper: to study the methods of implementation of technologies for early diagnosis and pharmacotherapy of pulmonary arterial hypertension and conceptual presentation of the results of their implementation.

The work used available scientific sources of information on the results of the implementation of diagnostic screening for early detection of PAH and pharmacotherapy in the world. The analysis of input data was carried out using systematic, documentary, informational and graphical research methods.

The result of the analysis of information materials showed that over the past two decades, significant progress has been made in the treatment of PAH and more than doubled the survival rate of patients.

It has been found that diagnostic screening is a relatively unique medical technology in relation to other medical interventions and can be defined as the systematic use of diagnostic technologies in individuals at risk to detect the disease before the onset of symptoms.

The study proposes a systematic concept of economic evaluation of the diagnostic screening program for PAH to determine its optimal design.

At the same time, this concept embodies the complex effect of the introduction of technologies for early diagnosis and pharmacotherapy of PAH, which is expressed in the positive dynamics of clinical indicators, reduced mortality and improved quality of life.

It should be noted that a number of new tools and approaches for diagnostic screening give hope that advances in the diagnosis of PAH will also affect the effectiveness of medical care.

References

Konstantinides S. V., Meyer G., Becattini C. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) // Eur. Respir. J. – 2019. – N 54. https://doi.org/10.1183/13993003.01647-2019

Ende-Verhaar Y. M., Huisman M. V., Klok F. A. To screen or not to screen for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism // Thromb. Res. – 2017. – N 151. – P. 1–7. https://doi.org/10.1016/j.thromres.2016.12.026

Boon G. J. A. M., Bogaard H. J., Klok F. A. Essential aspects of the follow-up after acute pulmonary embolism: an illustrated review // Res. Pract. Thromb. Haemost. – 2020. – N 4. – P. 958–968. https://doi.org/10.1002/rth2.12404

Boon G. J. A. M., Ende-Verhaar Y. M., Bavalia R. et al. Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II study // Thorax. – 2021. – N 76. – P. 1002–1009. https://doi.org/10.1136/thoraxjnl-2020-216324

Ende-Verhaar Y. M., Ruigrok D., Bogaard H. J. et al. Sensitivity of a simple noninvasive screening algorithm for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism // Thieme. – 2018. – N 2. – P. 89–95. https://doi.org/110.1055/s-0038-1636537

Ende-Verhaar Y. M., van den Hout W. B., Bogaard H. J. et al. Healthcare utilization in chronic thromboembolic pulmonary hypertension after acute pulmonary embolism // J. Thromb. Haemost. – 2018. – N 16. – P. 2168–2174. https://doi.org/10.1111/jth.14266

Klok F. A., Barco S., Konstantinides S. V. et al. Determinants of diagnostic delay in chronic thromboembolic pulmonary hypertension: results from the European CTEPH Registry // Eur. Respir. J. – 2018. – N 52. https://doi.org/10.1183/13993003.01687-2018

Brown L. M., Chen H., Halpern S. et al. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry // Chest. – 2011. – N 140. – P. 19–26. https://doi.org/10.1378/chest.10-1166

Humbert M., Yaici A., de Groote P. et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival // Arthritis Rheum. – 2011. – N 63. – P. 3522–3530. https://doi.org/10.1002/art.30541

Behr J., Nathan S. D. Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment // Current Opinion in Pulmonary Med. – 2021. – N 27. – P. 396–404. https://doi.org/10.1097/MCP.0000000000000790

Coquoz N., Weilenmann D., Stolz D. et al. Multicentre observational screening survey for the detection of CTEPH following pulmonary embolism // Eur. Respir. J. – 2018. – N 51. https://doi.org/10.1183/13993003.02505-2017

Boon G. J. A. M., Huisman M. V., Klok F. A. Why, whom, and how to screen for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism // Semin. Thromb. Hemost. – 2021. – N 47. – P. 692–701. https://doi.org/10.1055/s-0040-1718925

DU «Derzhavnyi ekspertnyi tsentr MOZ Ukrainy». Adaptovana klinichna nastanova [Elektronnyi resurs]. – Rezhym dostupu: dec.gov.ua/wp-content/uploads/2019/11/2016_614_akn_leggipert.pdf

Wong W. W., Hong- Ahn T., Feld J. et al. Cost-effectiveness of screening for hepatitis C in Canada // CMAJ. – 2015. – N 187. – P. 110–121. https://doi.org/10.1503/cmaj.140711

Aronsson M., Svennberg E., Rosenqvist M. et al. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording // Europace. – 2015. – N 17. – P. 1023–1029. https://doi.org/10.1093/europace/euv083

Alarid F., Enns E., Kuntz K. et al. «Time Traveling Is Just Too Dangerous» but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier // Value in Health. – 2019. – N 22. – P. 611–618. https://doi.org/10.1016/j.jval.2019.02.008

Akizuki A., Sugimura K., Aoki T. et al. Non-invasive screening using ventilatory gas analysis to distinguish between chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension // Wiley online library. – 2019. – N 25. – P. 343–457. https://doi.org/10.1111/resp.13618

Published
2022-10-29
How to Cite
Datsenko, I. S., & Kabachna, A. V. (2022). Scientific substantiation of the concept of pharmacoeconomic analysis of technologies for early diagnosis and pharmacotherapy of pulmonary arterial hypertension. Farmatsevtychnyi Zhurnal, (5), 57-64. https://doi.org/10.32352/0367-3057.5.22.06
Section
Pharmacoeconomics

Most read articles by the same author(s)